Endocan: A Novel Marker of Endothelial Dysfunction in C1-Inhibitor-Deficient Hereditary Angioedema.

Demirturk M., Akpinar T. S., Kose M., Gelincik A., Colakoglu B., Buyukozturk S.

International archives of allergy and immunology, vol.174, no.2, pp.104-107, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 174 Issue: 2
  • Publication Date: 2017
  • Doi Number: 10.1159/000481256
  • Journal Name: International archives of allergy and immunology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.104-107
  • Keywords: C1-inhibitor deficiency, Endocan, Hereditary angioedema, Vascular cell adhesion molecules, CELL-SPECIFIC MOLECULE-1, IN-VIVO, ACTIVATION, ATHEROSCLEROSIS, COMPLEMENT, ATTACKS, SYSTEMS, ESM-1
  • Istanbul University Affiliated: Yes

Abstract

Background: Hereditary angioedema (HAE) related to C1-inhibitor deficiency is a rare autosomal dominant disorder. Vascular cell adhesion molecules (VCAM) are known as endothelial activation markers. Endocan (also called ESM-1) is proposed as an endothelial dysfunction indicator. We aimed to investigate endothelial activation in attack-free periods in HAE patients by measuring their levels of endocan and VCAM-1. Methods: Twenty-six HAE patients (22 female, mean age 40 +/- 13 years) and 38 healthy control patients (13 female, mean age 36.9 +/- 12 years) were included in the study. Peripheral blood samples were collected from HAE patients during symptom-free periods and control subjects. Endocan and VCAM-1 levels were measured using the enzyme-linked immunosorbent assay method. Results: The median serum levels of endocan (647 +/- 101 ng/mL) and VCAM-1 (500 +/- 79 ng/mL) in the HAE patients were significantly higher than in the control patients (391 +/- 41 and 325 +/- 4; p < 0.001 for both). Conclusion: The increased endocan and VCAM-1 levels may reflect an endothelial activation even in attack-free periods in HAE patients. (C) 2017 S. Karger AG, Basel